GSK culls cancer, rare disease meds amid Q4 clear-out

It’s that time of year when Big Pharmas quietly dump unwanted and/or failed meds, and now it’s the turn of GlaxoSmithKline.

While spending much of its time talking up its newly announced CureVac COVID-19 manufacturing and development deal, tucked away in its fourth-quarter and full-year financials was the announcement of a mini drug cull.